Last reviewed · How we verify
Today (nonoxinol)
Today (nonoxinol) is a small molecule contraceptive medication originally developed by Personal Prods and currently owned by the same company. It was FDA approved in 1963 for use in contraception. The commercial status of Today is not explicitly stated, but it is likely to be a branded product given its ownership. Key safety considerations include potential irritation and allergic reactions. As a nonoxinol-based contraceptive, it works by disrupting sperm cell membranes.
At a glance
| Generic name | nonoxinol |
|---|---|
| Sponsor | Personal Prods |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1963 |
Approved indications
- Contraception
Common side effects
Key clinical trials
- AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment (NA)
- The K-Map Study, Global Prevalence of KC
- Effectiveness of SNAPPS in Family Medicine Residency Program (NA)
- Ovulation Double Check (Proov) Verification and Usability Testing
- The Contraceptive Efficacy and Safety of an Intravaginal Acetic Acid Thermoreversible Gel on Chinese Women. (PHASE2)
- Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel (PHASE3)
- Enhanced Perioperative Care for the Prevention of Colorectal Anastomotic Leakage (NA)
- A Study of the Effects of Advantage 24 on the Rectum (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Today CI brief — competitive landscape report
- Today updates RSS · CI watch RSS
- Personal Prods portfolio CI